The FDA has now rejected Intarcia’s exenatide implanted micropump for the second time, which may likely put an end to the device.  Intarcia received a Complete Response Letter from the FDA stating that their exenatide micropump that could be inserted under the skin and provided its GLP-1 medication for 3 or 6 months and eventually for a year, would not be approved at this time.